ACE2 and acute respiratory distress syndrome: Luckily, already existing data of phase II on safety of the other recombinant human soluble ACE2 (GSK2586881) in patients with acute respiratory distress syndrome (ARDS) (ClinicalTrials.gov: NCT01597635) and pulmonary arterial hypertension (NCT03177603) support the premise of its efficacy.